Osteopontin and multiple sclerosis: An update

Clinical and Experimental Neuroimmunology

Volumn 2, Issue 2, 2011, Pages 33-40

  Niino, Masaaki ^a   Kikuchi, Seiji ^a  

^a HOKKAIDO MEDICAL CENTER   (Japan)

Author keywords

cytokine; experimental autoimmune encephalomyelitis; genetic polymorphism; immune regulation; multiple sclerosis; osteopontin

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 12; OSTEOPONTIN;

ALLERGIC ENCEPHALOMYELITIS; CELL DIFFERENTIATION; CELL FUNCTION; CEREBROSPINAL FLUID; GENE; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 80051684782     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/j.1759-1961.2011.00019.x     Document Type: Review

References (68)

1. Lassmann F,. What drives disease in multiple sclerosis: inflammation or neurodegeneration? Clin Exp Neuroimmunol. 2010; 1: 2-11.
2. Sodek J, Ganss B, McKee MD,. Osteopontin. Crit Rev Oral Biol Med. 2000; 11: 279-303.
3. Wang KX, Denhardt DT,. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008; 19: 333-45.
4. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al., Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287: 860-4. (Pubitemid 30084330)
5. Rangaswami H, Bulbule A, Kundu GC,. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16: 79-87. (Pubitemid 43247403)
6. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC,. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets. 2007; 11: 81-90. (Pubitemid 46099754)
7. 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995; 77: 665-72.
8. Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R,. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J Biol Chem. 1995; 270: 23196-202.
9. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, et al., Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by a9b1 integrin. J Biol Chem. 1996; 271: 28485-91. (Pubitemid 26374670)
10. Bayless KJ, Meininger GA, Scholtz JM, Davis GE,. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci. 1998; 111: 1165-74.
11. Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST,. Structural elements of the osteopontin SVVYGLR motif important for the interaction with a4 integrins. FEBS Lett. 2001; 503: 75-9. (Pubitemid 32769959)
12. Kazanecki CC, Uzwiak DJ, Denhardt DT,. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007; 102: 912-24. (Pubitemid 350036931)
13. Gravallese EM,. Osteopontin: a bridge between bone and the immune system. J Clin Invest. 2003; 112: 147-9. (Pubitemid 38056349)
14. Saito Y, Kon S, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N, et al., Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther. 2007; 18: 1205-14. (Pubitemid 350261964)
15. Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H,. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci U S A. 2008; 105: 7235-9. (Pubitemid 351754461)
16. Cantor H, Shinohara ML,. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol. 2009; 9: 137-41.
17. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, et al., Osteopontin expression is essential for interferon-a production by plasmacytoid dendritic cells. Nat Immunol. 2006; 7: 498-506.
18. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H,. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci U S A. 2005; 102: 17101-6. (Pubitemid 41692690)
19. Zhao C, Fancy SP, ffrench-Constant C, Franklin RJ,. Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination. Neurobiol Dis. 2008; 31: 209-17.
20. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM,. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. 2006; 111: 289-99.
21. Selvaraju R, Bernasconi L, Losberger C, Graber P, Kadi L, Avellana-Adalid V, et al., Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol Cell Neurosci. 2004; 25: 707-21. (Pubitemid 38481478)
22. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS,. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001; 107: 1055-61. (Pubitemid 32422899)
23. + T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 2008; 181: 7480-8.
24. O'Regan A, Berman JS,. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000; 81: 373-90. (Pubitemid 32291179)
25. O'Regan AW, Hayden JM, Berman JS,. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol. 2000; 68: 495-502.
26. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H,. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin- deficient mice. J Immunol. 2002; 168: 2096-9. (Pubitemid 34171807)
27. Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS,. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol. 2008; 65: 633-5. (Pubitemid 351679658)
28. h2-polarized cells. Int Immunol. 2001; 13: 367-76. (Pubitemid 32179085)
29. Higuchi Y, Tamura Y, Uchida T, Matsuura K, Hijiya N, Yamamoto S,. The roles of soluble osteopontin using osteopontin-transgenic mice in vivo: proliferation of CD4+ T lymphocytes and the enhancement of cell-mediated immune responses. Pathobiology. 2004; 71: 1-11. (Pubitemid 37256021)
30. Weber GF, Ashkar S, Glimcher MJ, Cantor H,. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996; 271: 509-12. (Pubitemid 26044470)
31. Rothstein TL, Guo B,. Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin. J Intern Med. 2009; 265: 632-43.
32. Guo B, Tumang JR, Rothstein TL,. B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways. Mol Immunol. 2009; 46: 587-91.
33. Li Q, Lifson JD, Duan L, Schacker TW, Reilly C, Carlis J, et al., Potential roles of follicular dendritic cell-associated osteopontin in lymphoid follicle pathology and repair and in B cell regulation in HIV-1 and SIV infection. J Infect Dis. 2005; 192: 1269-76. (Pubitemid 41368429)
34. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, et al., Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol. 2004; 198: 155-67. (Pubitemid 38120976)
35. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M,. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998; 152: 353-8. (Pubitemid 28106380)
36. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, et al., Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity. 2004; 21: 539-50. (Pubitemid 39370509)
37. Rollo EE, Laskin DL, Denhardt DT,. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol. 1996; 60: 397-404. (Pubitemid 26325622)
38. Hofstetter H, Gold R, Hartung HP,. Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis. Int MS J. 2009; 16: 12-8.
39. Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC, et al., Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol. 2009; 39: 2525-36.
40. Shinohara ML, Kim JH, Garcia VA, Cantor H,. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: central role of intracellular osteopontin. Immunity. 2008; 29: 68-78.
41. Murugaiyan G, Mittal A, Weiner HL,. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-g limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A. 2010; 107: 11495-500.
42. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L,. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007; 8: 74-83. (Pubitemid 46242361)
43. Standal T, Borset M, Sundan A,. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004; 26: 179-84.
44. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al., The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001; 294: 1731-5. (Pubitemid 33104847)
45. Kim MD, Cho HJ, Shin T,. Expression of osteopontin and its ligand, CD44, in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004; 151: 78-84. (Pubitemid 38624402)
46. Blom T, Franzén A, HeinegÃrd D, Holmdahl R,. Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease". Science. 2003; 299: 1845.
47. GoncalvesDaSilva A, Liaw L, Yong VW,. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol. 2010; 177: 1448-58.
48. Choi JS, Park HJ, Cha JH, Chung JW, Chun MH, Lee MY,. Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol. 2003; 141: 65-73.
49. Tajouri L, Mellick AS, Tourtellotte A, Nagra RM, Griffiths LR,. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis. Brain Res Brain Res Protoc. 2005; 15: 79-91. (Pubitemid 40828888)
50. Koning N, Bö L, Hoek RM, Huitinga I,. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol. 2007; 62: 504-14. (Pubitemid 350308775)
51. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S,. Up-regulation of osteopontin and aB-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol. 2005; 31: 292-303. (Pubitemid 40769528)
52. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, et al., Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005; 158: 231-9. (Pubitemid 39626091)
53. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L,. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol. 2003; 53: 819-22. (Pubitemid 36622524)
54. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, et al., Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol. 2004; 155: 155-60. (Pubitemid 39165788)
55. Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R,. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010; 16: 443-9.
56. Chowdhury SA, Lin J, Sadiq SA,. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol. 2008; 65: 232-5. (Pubitemid 351240786)
57. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al., Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006; 59: 748-54. (Pubitemid 43673152)
58. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al., The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009; 16: 528-36.
59. Niino M, Fukazawa T, Kikuchi S, Sasaki H,. Recent advances in genetic analysis of multiple sclerosis: genetic associations and therapeutic implications. Expert Rev Neurother. 2007; 7: 1175-88. (Pubitemid 47451024)
60. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K,. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003; 136: 125-9. (Pubitemid 36298851)
61. Hensiek AE, Roxburgh R, Meranian M, Seaman S, Yeo T, Compston DA, et al., Osteopontin gene and clinical severity of multiple sclerosis. J Neurol. 2003; 250: 943-7. (Pubitemid 37041025)
62. Caillier S, Barcellos LF, Baranzini SE, Swerdlin A, Lincoln RR, Steinman L, et al., Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 2003; 4: 312-5. (Pubitemid 39562131)
63. Mas A, Martínez A, de lasHeras V, Bartolomé M, de la Concha EG, Arroyo R, et al., The 795CT polymorphism in osteopontin gene is not associated with multiple sclerosis in a Spanish population. Mult Scler. 2007; 13: 250-2. (Pubitemid 46592779)
64. Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, et al., High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood. 2004; 103: 1376-82. (Pubitemid 38168652)
65. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, et al., Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol. 2005; 163: 172-8. (Pubitemid 40692960)
66. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, et al., SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol. 2005; 40: 381-8. (Pubitemid 40723929)
67. Steinman L,. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN. Eur J Immunol. 2009; 39: 2358-60.
68. Steinman L,. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009; 9: 440-7.